表紙
市場調查報告書

幹細胞治療的浮沉:現有解決辦法

Highs and Lows of Stem Cell Therapies: Off - The-Shelf Solutions

出版商 BCC Research 商品編碼 920049
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
幹細胞治療的浮沉:現有解決辦法 Highs and Lows of Stem Cell Therapies: Off - The-Shelf Solutions
出版日期: 2019年12月23日內容資訊: 英文 25 Pages
簡介

本報告提供幹細胞治療調查分析,最近的進步概要,安全有效的治療選擇,3D細胞培養相關資訊,遺傳基因編輯、遺傳基因編程技術的進步,商業、規定形勢等相關的系統性資訊。

第1章 幹細胞治療的起源與特徵

  • 簡介

第2章 促進幹細胞發生的新的技術

  • 細胞培養的進步
  • 分離技術的進步
  • 基因操作的進步

第3章 安全性,有效性,物流上的課題

  • 毒性相關的治療的問題
  • 物流上的課題

第4章 現有解決辦法

  • 幹細胞治療的擴大
  • 更精密的細胞的基因操作
  • 細胞間變異的減少
  • 保存可能期間的改善

第5章 值得注意的企業及技術

  • Athersys Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Caladrius Biosciences
  • Cellular Biomedicine Group Inc.
  • Fate Therapeutics Inc.
  • Gamida Cell Ltd.
  • International Stem Cell Corporation
  • Orgenesis Inc.
  • Pluristem Therapeutics Inc.
  • Sangamo Therapeutics Inc.
  • TheraCell Inc.
  • ThermoGenesis Holdings
  • Vericel Corporation
  • VistaGen Therapeutics Inc.
  • Zelluna Immunotherapy Inc.

第6章 參考資料

目錄
Product Code: BIO199A

Report Highlights:

This report will review the current commercial and regulatory landscape for the stem cell therapies, and assesses the challenges and opportunities for developing autologous and allogenic “off the shelf” solutions to treat a broad range of diseases and injuries.

Report Includes:

  • An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies
  • Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options
  • Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs)
  • Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers
  • Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic "off the shelf" solutions

Table of Contents

Chapter 1: Sources and Characteristics of Stem Cells

  • Introduction

Chapter 2: New Technologies Driving Stem Cell Development

  • Advances in Cell Culture
  • Advances in Isolation Technologies
  • Advances in Genome Manipulation

Chapter 3: Safety, Efficacy and Logistical Challenges

  • Toxicity-Related Treatment Issues
  • Logistical Challenges

Chapter 4: Off-the-Shelf Solutions

  • Expanding the Course of Stem Cells
  • More Precise Genomic Manipulation of Cells
  • Reduction in Cell-to-Cell Variation
  • Improved Shelf Life

Chapter 5: Companies and Technologies to Watch

  • Athersys Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Caladrius Biosciences
  • Cellular Biomedicine Group Inc.
  • Fate Therapeutics Inc.
  • Gamida Cell Ltd.
  • International Stem Cell Corporation
  • Orgenesis Inc.
  • Pluristem Therapeutics Inc.
  • Sangamo Therapeutics Inc.
  • TheraCell Inc.
  • ThermoGenesis Holdings
  • Vericel Corporation
  • VistaGen Therapeutics Inc.
  • Zelluna Immunotherapy Inc.
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 6: References

List of Tables

  • Table 1: Stem Cell Sources
  • Table 2: Comparison of Stem Cells
  • Table 3: Stem Cell Types Versus Cell Properties
  • Table 4: Recent Advances in Genome Modulation Technologies
  • Table 5: FDA-Approved Cell-Based Therapies
  • Table 6: Acute and Delayed Adverse Events Associated with Proven and Unproven Stem Cell-Based Interventions
  • Table 7: Companies Leading the Field in Cell-Based Therapies

List of Figures

  • Figure 1: Stem Cell Sources
  • Figure 2: Two-Dimensional Versus Three-Dimensional Cell Culture
  • Figure 3: Schematic of Approaches Used for Three-Dimensional Stem Cell Culture
  • Figure 4: Patient Management Strategies to Decrease Side Effects Related with CAR-T Cell Therapy
Back to Top